Forest Laboratories, Inc. and Gedeon Richter Ltd. Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment of Schizophrenia
NEW YORK & BUDAPEST, Hungary--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc today announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.